Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Assets (2016 - 2025)

Historic Assets for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $6.2 million.

  • Ernexa Therapeutics' Assets fell 2003.11% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 2003.11%. This contributed to the annual value of $5.3 million for FY2024, which is 8927.58% down from last year.
  • Ernexa Therapeutics' Assets amounted to $6.2 million in Q3 2025, which was down 2003.11% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Assets ranged from a high of $64.7 million in Q2 2021 and a low of $5.1 million during Q1 2025
  • Moreover, its 5-year median value for Assets was $24.6 million (2022), whereas its average is $29.0 million.
  • In the last 5 years, Ernexa Therapeutics' Assets soared by 67946.9% in 2021 and then crashed by 8981.21% in 2025.
  • Ernexa Therapeutics' Assets (Quarter) stood at $39.4 million in 2021, then crashed by 43.45% to $22.3 million in 2022, then soared by 120.53% to $49.1 million in 2023, then tumbled by 89.28% to $5.3 million in 2024, then rose by 17.14% to $6.2 million in 2025.
  • Its Assets was $6.2 million in Q3 2025, compared to $7.6 million in Q2 2025 and $5.1 million in Q1 2025.